Business: targets the world’s two leading causes of blindness with its unique technology, which provides continuous topical treatment of both the anterior segment of the eye and the retina, freeing patients from invasive and costly eye drops or intraocular injections.
_____________________________________
Sector : Health
________________________________________
Investment Date : March 2024
________________________________________
Fund : GOCA3